A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant

Biol Blood Marrow Transplant. 2019 Oct;25(10):e305-e309. doi: 10.1016/j.bbmt.2019.07.003. Epub 2019 Jul 8.

Abstract

Bloodless autologous hematopoietic cell transplantation is associated with risks of severe bleeding and profound anemia. RBC or platelet transfusions are often used to prevent these hematologic complications. However, in patients such as Jehovah's Witnesses who refuse major blood components, the lack of transfusion support is not an absolute contraindication to an autologous hematopoietic cell transplant. Pennsylvania Hospital performed the world's first bloodless hematopoietic cell transplant more than 15 years ago and has gradually improved its technique with a sizable patient population. Erythropoiesis-stimulating agents were successfully employed as part of their pretransplant regimen to prevent severe anemia. Thrombopoietin agonists' potential role in bloodless transplant is also currently being explored. Although there is limited literature, available reports in combination with physiologic reasoning may support the use of these growth factors to promote transplant success. These agents offer potential benefit and may be of utility in minimizing complications of a bloodless transplant. In this review, we summarize the available literature and offer insight into how we may incorporate growth factors to allow bloodless autologous hematopoietic cell transplantation to be an available option to patients who may otherwise be denied.

Keywords: Bloodless transplant; Erythropoiesis-stimulating agents; Erythropoietin; Jehovah's Witness; Romiplostim; Thrombopoietin.

Publication types

  • Review

MeSH terms

  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Jehovah's Witnesses
  • Thrombopoietin / metabolism*
  • Transplantation Conditioning / methods*
  • Transplantation, Autologous / methods*

Substances

  • Thrombopoietin